132 related articles for article (PubMed ID: 21288105)
21. [Is endometriosis a precancerous lesion? Perspectives and clinical implications].
Chene G; Caloone J; Moret S; Le Bail-Carval K; Chabert P; Beaufils E; Mellier G; Lamblin G
Gynecol Obstet Fertil; 2016 Feb; 44(2):106-12. PubMed ID: 26850282
[TBL] [Abstract][Full Text] [Related]
22. Endometriosis and the neoplastic process.
Varma R; Rollason T; Gupta JK; Maher ER
Reproduction; 2004 Mar; 127(3):293-304. PubMed ID: 15016949
[TBL] [Abstract][Full Text] [Related]
23. Endometrioid adenocarcinoma of the ovary arising from endometriosis and presenting as an acute abdomen.
Maruthini D; Amin A; Buxton J
J Obstet Gynaecol; 2007 Jul; 27(5):540-1. PubMed ID: 17701820
[No Abstract] [Full Text] [Related]
24. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
25. A series of ovarian clear cell and endometrioid carcinoma and their association with endometriosis.
Chew S; Tham KF; Ratnam SS
Singapore Med J; 1997 Jul; 38(7):289-91. PubMed ID: 9339094
[TBL] [Abstract][Full Text] [Related]
26. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Anglesio MS; Bashashati A; Wang YK; Senz J; Ha G; Yang W; Aniba MR; Prentice LM; Farahani H; Li Chang H; Karnezis AN; Marra MA; Yong PJ; Hirst M; Gilks B; Shah SP; Huntsman DG
J Pathol; 2015 Jun; 236(2):201-9. PubMed ID: 25692284
[TBL] [Abstract][Full Text] [Related]
27. MiR‑381 regulates cell motility, growth and colony formation through PIK3CA in endometriosis‑associated clear cell and endometrioid ovarian cancer.
Hsu CY; Hsieh TH; Er TK; Chen HS; Tsai CC; Tsai EM
Oncol Rep; 2018 Dec; 40(6):3734-3742. PubMed ID: 30542723
[TBL] [Abstract][Full Text] [Related]
28. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis.
Stewart CJ; Leung Y; Walsh MD; Walters RJ; Young JP; Buchanan DD
Hum Pathol; 2012 Aug; 43(8):1177-83. PubMed ID: 22305241
[TBL] [Abstract][Full Text] [Related]
29. Endometriosis-associated ovarian carcinomas.
Birnbaum DJ; Birnbaum D; Bertucci F
N Engl J Med; 2011 Feb; 364(5):483-4; author reply 484-5. PubMed ID: 21288104
[No Abstract] [Full Text] [Related]
30. Molecular pathogenesis of ovarian clear cell carcinoma.
Gounaris I; Brenton JD
Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer.
Prowse AH; Manek S; Varma R; Liu J; Godwin AK; Maher ER; Tomlinson IP; Kennedy SH
Int J Cancer; 2006 Aug; 119(3):556-62. PubMed ID: 16506222
[TBL] [Abstract][Full Text] [Related]
32. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
34. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE; Miller A; Soslow RA; Lankes HA; DeLair D; Segura S; Chavan S; Zamarin D; DeBernardo R; Moore K; Moroney J; Shahin M; Thaker PH; Wahner-Hendrickson AE; Aghajanian C
Gynecol Oncol; 2023 Sep; 176():16-24. PubMed ID: 37418832
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics of ovarian carcinomas associated with endometriosis.
Kondi-Pafiti A; Papakonstantinou E; Iavazzo C; Grigoriadis C; Salakos N; Gregoriou O
Arch Gynecol Obstet; 2012 Feb; 285(2):479-83. PubMed ID: 21717140
[TBL] [Abstract][Full Text] [Related]
37. [Ovarian clear cell borderline tumour: a clinicopathologic analysis].
Gu WY; Zhang LL; Zhang H; Pan QZ; Qu YQ; Tao X; Ning Y
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):622-626. PubMed ID: 30107668
[No Abstract] [Full Text] [Related]
38. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
[TBL] [Abstract][Full Text] [Related]
39. Analysis of p53 and c-erbB-2 expression in ovarian endometrioid carcinomas arising in endometriosis.
Prefumo F; Venturini PL; Fulcheri E
Int J Gynecol Pathol; 2003 Jan; 22(1):83-8. PubMed ID: 12496703
[TBL] [Abstract][Full Text] [Related]
40. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
